title: SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma.
abstract: Gastric cancer is the second most common cause of cancer-related death worldwide, and the incidence of esophageal adenocarcinoma is rising. While some progress has been made in treatment strategies, overall survival remains very poor for patients with adenocarcinoma in the upper gastrointestinal tract. Special AT-rich sequence binding protein 1 (SATB1) is a global genome organizer that has been demonstrated to promote aggressive tumor behavior in several different types of cancer, including gastric cancer. The prognostic value of SATB1 expression in esophageal cancer has, however, not yet been described. In this study, expression of SATB1 was examined by immunohistochemistry on tissue microarrays prepared from tissue samples from 175 patients with adenocarcinoma of the esophagus, cardia, or stomach and containing normal tissue, intestinal metaplasia, primary tumors, and metastases. A well-validated antibody was used. We found SATB1 to be an independent prognostic factor in patients with a radically resected tumor, correlating with shorter overall survival as well as with shorter recurrence-free survival. SATB1 expression was also found to be significantly lower in primary tumors associated with intestinal metaplasia than those without intestinal metaplasia. This observation is of potential biological interest as it has been proposed that intestinal metaplasia-associated tumors constitute a less aggressive phenotype.
authors.affiliation: Department of Clinical Sciences, Division of Oncology and Pathology, Lund University, Skåne University Hospital, 221 85, Lund, Sweden, charlotta.hedner@med.lu.se.
authors.forename: Charlotta
authors.initials: C
authors.lastname: Hedner
authors.forename: Alexander
authors.initials: A
authors.lastname: Gaber
authors.forename: Dejan
authors.initials: D
authors.lastname: Korkocic
authors.forename: Björn
authors.initials: B
authors.lastname: Nodin
authors.forename: Mathias
authors.initials: M
authors.lastname: Uhlén
authors.forename: Eugenia
authors.initials: E
authors.lastname: Kuteeva
authors.forename: Henrik
authors.initials: H
authors.lastname: Johannesson
authors.forename: Karin
authors.initials: K
authors.lastname: Jirström
authors.forename: Jakob
authors.initials: J
authors.lastname: Eberhard
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D015153:Blotting, Western; D002299:Cardia / Q000473:pathology; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D036961:Matrix Attachment Region Binding Proteins / Q000032:analysis / Q000096:biosynthesis*; D008875:Middle Aged; D011230:Precancerous Conditions / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000378:metabolism / Q000401:mortality / Q000473:pathology*; D046888:Tissue Array Analysis
chemical_list: D014408:Biomarkers, Tumor; D036961:Matrix Attachment Region Binding Proteins; C076189:SATB1 protein, human